Licensing trials should record all adverse results and be made public

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1427, 2004-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RECORD results for rivaroxaban in VTE prevention

By  

Inpharma, Vol. 1, Iss. 1646, 2008-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Everolimus results go on RECORD early

By  

Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Hypertension trials should focus on key clinical questions

By  

Inpharma, Vol. 1, Iss. 1535, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Compulsory pharmaceutical patent licensing in Brazil: the controversy of public interest

By Rodrigues da Silva Caio   Galvão de Botton Leonor  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 6, 2013-11 ,pp. : 685-687

Future Science

Access to resources Recommend Favorite

Presenting the results of clinical trials to participants

By Darbyshire Julie L   Holman Rury R   Price Hermione C  

Clinical Medicine, Vol. 9, Iss. 5, 2009-10 ,pp. : 415-416

Royal College Of Physicians

Access to resources Recommend Favorite